Trilipix is owned by Abbvie.
Trilipix contains Choline Fenofibrate.
Trilipix has a total of 1 drug patent out of which 0 drug patents have expired.
Trilipix was authorised for market use on 15 December, 2008.
Trilipix is available in capsule, delayed release;oral dosage forms.
The generics of Trilipix are possible to be released after 07 January, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7259186||ABBVIE||Salts of fenofibric acid and pharmaceutical formulations thereof|| |
(1 year, 10 months from now)
Market Authorisation Date: 15 December, 2008
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic